June 3, 2022
The Globe and Mail | Repare stock soars after Montreal cancer drug developer strikes US$1-billion-plus deal with Roche
David Martin, Head of Bloom Burton Equity Research shares his thoughts on the licensing deal between Repare Therapeutics Inc. (NASDAQ: RPTX) and pharmaceutical giant, Roche:
